Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

Inclusion Criteria:

• Diagnosis of active UC defined on clinical grounds (Partial Mayo score ≥ 3 with eachsubscore >1)
• Sexually active male and female subjects of childbearing potential must agree to usean effective method of birth control during the study.
• Female subjects of childbearing potential must have a negative urine Qualitative HumanChorionic Gonadotropin(HCG)pregnancy test at enrolment and on the Week 1, Day 1 of theTreatment prior to administration of study drug.
• Willing and able to sign an informed consent form and attend all study-related clinicvisits, assessments, and follow-up phone calls.
• Subject has an attending physician who will provide the non-FMT care.

Exclusion Criteria:

• Subjects with sever UC (Mayo score of >7)
• Unable to take retention enema or multiple capsules orally.
• Females who are pregnant, breastfeeding, or planning to become pregnant during thestudy.
• Receipt of systemic non-topical antibiotics within 14 days of treatment day 1.
• Positive results for active HIV, Hepatitis B, or Hepatitis C infections.
• History of recurrent Clostridium difficile infection or FMT in the past 6-months.
• History of other active gastrointestinal conditions such as irritable bowel syndrome,microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy,gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitisetc.
• Known history of bile acid diarrhea
• Compromised immune system (e.g. primary immune disorders or clinical immunosuppressiondue to a medical condition or medication e.g. taking oral prednisone >20 mg a day orprednisone-equivalent)
• History of active cancer and/or ongoing chemotherapy (superficial non-metastaticcancers and maintenance chemotherapy are permitted).
• History of use of an investigational drug within 90 days prior to the screening visit.
• History of significant uncontrolled systemic disease that in the opinion of the studyinvestigator could interfere with study participation and/or objectives.
• Life expectancy of < 1 year.
• In the opinion of investigator, subject for any reason, should be excluded from thestudy.
• Absolute neutrophil count (ANC) < 500IU/mL